This question was closed without grading. Reason: Other
Mar 15, 2018 16:15
6 yrs ago
2 viewers *
English term
PHARMACY - LIFE SCIENCES
Native in: Russian
Works in: English to Russian, Russian to English
first filing acceptance
English to Russian
Medical
Medical: Pharmaceuticals
The application is seeking approval for KEYTRUDA as a treatment for patients with advanced cervical cancer with disease progression on or after chemotherapy.
This is the first filing acceptance and Priority Review granted for an anti-PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA.
This is the first filing acceptance and Priority Review granted for an anti-PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA.
Proposed translations
(Russian)
| 4 | первая подача заявки |
Vladyslav Golovaty
|
| 4 | here: from the day of acceptance of filing - со дня принятия заявки |
Erzsébet Czopyk
|
Proposed translations
1 hr
Vladyslav Golovaty
Ukraine
Ukraine
Native in English
&
Russian
Works in field
Ukraine
a top-rank. native English-Ukrainian-Rus
Native in: English (Variant: US) 
, Ukrainian (Variant: Standard-Ukraine) 
, Russian
Works in: English to Ukrainian, Ukrainian to English, Russian to English, and 3 more.
Related KudoZ points
:
217
первая подача заявки
Относительно «новизны» активного ингредиента не уточняется, имеется ли в виду первая подача заявки в стране или в мире. https://www.apteka.ua/article/3531
2 days 20 hrs
Erzsébet Czopyk
Hungary
Hungary
Specializes in field
Hungary
sworn translator, linguist, DPO
Native in: Hungarian (Variant: Hungary)
Works in: Russian to Hungarian, Hungarian to Russian, Latvian to Russian, and 10 more.
Related KudoZ points
:
215
here: from the day of acceptance of filing - со дня принятия заявки
Your text:
FDA Grants Priority Review to Merck's Supplemental Biologics ...
https://www.dddmag.com/.../fda-grants-priority-review-mercks...
- This is the first filing acceptance and Priority Review granted for an anti-PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA for KEYTRUDA. The FDA has set a PDUFA, or target action, date of June 28, 2018. “Advanced cervical cancer is an illness with a poor prognosis ...
http://ir.amicusrx.com/news-releases/news-release-details/us...
CRANBURY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision medicine migalastat HCl (“migalastat”) for the treatment of patients 16 years and older with Fabry disease who have amenable mutations. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA decision is August 13, 2018.
Migalastat previously received both Orphan Drug Designation and Fast Track designation from the U.S. FDA. The FDA’s Priority Review status accelerates the review time from 10 months to a goal of six months from the day of acceptance of filing and is given to drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists.
Приоритетный обзор FDA ускорит время обзора с 10 месяцев до полных шести месяцев со дня принятия заявки
Газета Поиск: Своими клетками
www.poisknews.ru/news/digest/27556/ - Translate this page
Jul 28, 2017 - Американское Управление по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA)
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:34:46 GMT)
--------------------------------------------------
Thank you very much Evgeni, your remark was very helpful
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:37:45 GMT)
--------------------------------------------------
Создание нового торгового названия лекарства » Клиническая ...
clinical-pharmacy.ru/.../414-sozdanie-novogo-torgovogo-nazvaniy...
В состав группы входит 15 экспертов, которые в течение 18 мес ***с момента подачи заявки*** (this is just filing but not filing acceptance!)*** должны принять решение по предлагаемому торговому названию лекарственного средства. В отличие от FDA, которое опубликовало свои специальные критерии оценки торговых названий ...
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:38:56 GMT)
--------------------------------------------------
EMA и FDA приняли заявки на регистрацию применения ...
m.clinvest.ru/.../ema-i-fda-prinyali-zayavki-na-registratsiyu-primen... -
Управление по контролю за продуктами и лекарствами США (FDA) также приняло к рассмотрению заявку
FDA Grants Priority Review to Merck's Supplemental Biologics ...
https://www.dddmag.com/.../fda-grants-priority-review-mercks...
- This is the first filing acceptance and Priority Review granted for an anti-PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA for KEYTRUDA. The FDA has set a PDUFA, or target action, date of June 28, 2018. “Advanced cervical cancer is an illness with a poor prognosis ...
http://ir.amicusrx.com/news-releases/news-release-details/us...
CRANBURY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision medicine migalastat HCl (“migalastat”) for the treatment of patients 16 years and older with Fabry disease who have amenable mutations. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA decision is August 13, 2018.
Migalastat previously received both Orphan Drug Designation and Fast Track designation from the U.S. FDA. The FDA’s Priority Review status accelerates the review time from 10 months to a goal of six months from the day of acceptance of filing and is given to drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists.
Приоритетный обзор FDA ускорит время обзора с 10 месяцев до полных шести месяцев со дня принятия заявки
Газета Поиск: Своими клетками
www.poisknews.ru/news/digest/27556/ - Translate this page
Jul 28, 2017 - Американское Управление по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA)
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:34:46 GMT)
--------------------------------------------------
Thank you very much Evgeni, your remark was very helpful
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:37:45 GMT)
--------------------------------------------------
Создание нового торгового названия лекарства » Клиническая ...
clinical-pharmacy.ru/.../414-sozdanie-novogo-torgovogo-nazvaniy...
В состав группы входит 15 экспертов, которые в течение 18 мес ***с момента подачи заявки*** (this is just filing but not filing acceptance!)*** должны принять решение по предлагаемому торговому названию лекарственного средства. В отличие от FDA, которое опубликовало свои специальные критерии оценки торговых названий ...
--------------------------------------------------
Note added at 2 days 20 hrs (2018-03-18 12:38:56 GMT)
--------------------------------------------------
EMA и FDA приняли заявки на регистрацию применения ...
m.clinvest.ru/.../ema-i-fda-prinyali-zayavki-na-registratsiyu-primen... -
Управление по контролю за продуктами и лекарствами США (FDA) также приняло к рассмотрению заявку
Something went wrong...